Less Ads, More Data, More Tools Register for FREE

Pin to quick picksYGEN.L Regulatory News (YGEN)

  • There is currently no data for YGEN

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Yourgene raises IONA® test awareness in Egypt

25 Mar 2019 07:00

RNS Number : 7996T
Yourgene Health PLC
25 March 2019
 

Yourgene Health plc

("Yourgene" or the "Company")

 

Yourgene raises IONA® test awareness in Egypt with British Ambassador

 

Manchester, UK - 25 March 2019: Yourgene Health (AIM: YGEN), the international molecular diagnostics group which commercialises genetic products and services, has held an event in Egypt to raise awareness of the IONA® test, a non-invasive prenatal DNA test for Down's syndrome, amongst the clinical community.

 

The event was attended by His Excellency Sir Geoffrey Adams, the British Ambassador to Egypt; and a number of key customers and medical professionals. Attendees heard from leading specialists in the prenatal field, including from the National Research Centre in Egypt and Ain Shams University's Faculty of Medicine.

 

British Ambassador in Egypt Sir Geoffrey Adams said: "The partnership between Egypt and the UK keeps on delivering new successes for both our countries. Today, British company Yourgene is bringing its latest technology to support the modernisation of the Egyptian healthcare system and offer world-class services for its citizens."

 

Lyn Rees, CEO of Yourgene, commented: "With a population of almost 100 million and a desire to offer high quality genetic analysis, we believe the market in Egypt could become a significant one for Yourgene going forward. We look forward to continuing to work with our local partners to deliver safe, fast and highly accurate prenatal screening solutions to pregnant women across Egypt."

 

Yourgene's IONA® test estimates the risk of a fetus being affected with Down's syndrome or other genetic conditions. The test is performed on a maternal blood sample, containing traces of fetal DNA, which is then analysed using next generation DNA sequencing technology. The test is highly accurate and significantly reduces the number of women who are unnecessarily subjected to risky, invasive follow up procedures to diagnose Down's syndrome and other genetic conditions.

 

 

For more information, please contact:

 

 

Yourgene Health plc

Lyn Rees, Chief Executive Officer

Barry Hextall, Chief Financial Officer

Joanne Cross, Head of Marketing

investors@yourgene-health.com

 

Tel: +44 (0)161 667 1053

 

 

Vigo Communications

Ben Simons / Fiona Henson / Antonia Pollock

yourgene@vigocomms.com

Tel: +44 (0)20 7390 0238

 

 

 

About Yourgene Health

Yourgene Health is an international molecular diagnostics group which develops and commercialises genetic products and services. The group works in partnership with global leaders in DNA technology to advance diagnostic science. 

 

Our product development, research service and commercial capabilities extend across the lifecycle of genetic test development including regulatory submissions.

 

Yourgene Health's first commercialised products are non-invasive prenatal tests (NIPT) for Down's syndrome and other genetic disorders, targeting a share of an emerging billion-dollar global market.

 

Prenatal screening is an established clinical practice, but accuracy challenges with traditional methods are driving the need for NIPT and other DNA-based reproductive health testing solutions. Yourgene Health's customer-focused products and services support all types of customer, irrespective of size, geography and market maturity. Our commercial footprint is already established in the UK, Europe, the Middle East, Africa and Asia.

 

Through our technical expertise and partnerships, Yourgene Health is aiming to extend its genetic testing offering into complementary areas of reproductive health and oncology.

 

Yourgene Health is headquartered in Manchester, UK with offices in Taipei and Singapore. For more information visit www.yourgene-health.com and follow us on twitter @Yourgene_Health.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
NRALFFSIVVIFFIA
Date   Source Headline
30th Nov 201511:20 amRNSNotice of Results
12th Nov 20157:00 amRNSPositive independent study results for IONA test
28th Oct 20157:00 amRNSAppointment to the Board
15th Oct 20153:56 pmRNSWorld first: in-house antenatal reflex screening
14th Oct 20157:00 amRNSClinical laboratory with expanded capacity opened
14th Oct 20157:00 amRNSHolding(s) in Company
13th Oct 20154:08 pmRNSResult of AGM
13th Oct 20152:20 pmRNSHolding(s) in Company
13th Oct 20157:01 amRNSAGM Statement
13th Oct 20157:00 amRNSPremaitha collaborates with Wolfson screening lab
12th Oct 20157:00 amRNSIndependent study of the IONA® test published
2nd Oct 20157:00 amRNSPremaitha appoints Greek distributor
1st Oct 20154:14 pmRNSPatent Infringement Proceedings Update
22nd Sep 20157:00 amRNSFinal Results
22nd Sep 20157:00 amRNSPremaitha signs contract for IONA test in Chile
15th Jul 20157:00 amRNSGrant of Options
13th Jul 20152:04 pmRNSHolding(s) in Company
6th Jul 20157:00 amRNSCQC accreditation for new NIPT lab
2nd Jul 20152:59 pmRNSCompletion of placing to raise £8 million
2nd Jul 20157:00 amRNSProposed placing to raise approximately £8 million
24th Jun 20157:00 amRNSNew IONA test clinical data showcased
22nd Jun 20157:00 amRNSNew contract for IONA® test
19th Jun 20157:00 amRNSTrading Update
4th Jun 20157:00 amRNSAppointment of Chief Financial Officer
5th May 20157:01 amRNSPremaitha Files Robust Defence with UK High Court
29th Apr 20151:53 pmRNSReissue of Options
31st Mar 20157:00 amRNSNew Contract for IONA test in Poland
23rd Mar 20159:53 amRNSLondon NHS trust teams up with Premaitha Health
16th Mar 20159:40 amRNSNotice of Patent Infringement Proceedings
16th Mar 20157:00 amRNSPremaitha Health signs first NIPT agreement
5th Feb 20157:00 amRNSCE Mark and Launch of the IONA test
30th Jan 20157:00 amRNSCommercial Launch Preparation Update
10th Dec 20147:00 amRNSResults for 7 months to 30 September 2014
25th Nov 20147:00 amRNSNotice of Half Year Results and IONA Test Showcase
4th Nov 201412:07 pmRNSResult of AGM
4th Nov 20147:00 amRNSAGM Statement
2nd Oct 20147:00 amRNSGrant of Options
30th Sep 20147:00 amRNSPublication of Annual Report and Notice of AGM
7th Jul 20144:47 pmRNSHolding(s) in Company
4th Jul 20144:28 pmRNSHolding(s) in Company
4th Jul 20147:00 amRNSFirst Day of Dealings on AIM
3rd Jul 20143:42 pmRNSChange of Name
3rd Jul 201411:36 amRNSResult of EGM
1st Jul 201410:47 amRNSOpen Offer Oversubcribed
13th Jun 20147:30 amRNSRestoration - ViaLogy Plc
13th Jun 20147:30 amRNSSchedule 1 - ViaLogy Plc
13th Jun 20147:00 amRNSPublication of Admission Document & Lifting of...
13th Jun 20147:00 amRNSDirectorate Change
13th Jun 20147:00 amRNSFinal Results
15th Apr 201412:30 pmRNSSuspension - Vialogy plc

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.